← 治験一覧に戻る
進行性固形腫瘍患者における化学放射線療法と免疫療法の併用
基本情報
- NCT ID
- NCT03509012
- ステータス
- 完了
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 105
- 治験依頼者名
- AstraZeneca
概要
This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors
対象疾患
Carcinoma, Squamous Cell of Head and NeckCarcinoma, Non-Small-Cell LungSmall Cell Lung Carcinoma
介入
Durvalumab(DRUG)
Tremelimumab(DRUG)
Cisplatin (dose level 4)(DRUG)
Cisplatin (dose level 3)(DRUG)
Carboplatin (dose level 1)(DRUG)
Carboplatin (dose level 2)(DRUG)
Etoposide (dose level 1)(DRUG)
Etoposide (dose level 2)(DRUG)
Paclitaxel(DRUG)
Pemetrexed(DRUG)
External beam radiation (dose level 1)(RADIATION)
External beam radiation (dose level 2)(RADIATION)
External beam radiation (hyperfractionated)(RADIATION)
Cisplatin (dose level 1)(DRUG)
Cisplatin (dose level 2)(DRUG)
External beam radiation (standard)(RADIATION)
依頼者（Sponsor）
アストラゼネカ株式会社(INDUSTRY)